These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8537682)

  • 21. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.
    Davis D; Donners H; Willems B; Lövgren-Bengtsson K; Akerblom L; Vanham G; Barnett S; Morein B; Heeney JL; van der Groen G
    Vaccine; 2004 Jan; 22(5-6):747-54. PubMed ID: 14741168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Newman FK; Belshe RB; Berman PW; Gregory TJ; Matthews TJ
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):378-86. PubMed ID: 8807200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.
    Zolla-Pazner S; Lubeck M; Xu S; Burda S; Natuk RJ; Sinangil F; Steimer K; Gallo RC; Eichberg JW; Matthews T; Robert-Guroff M
    J Virol; 1998 Feb; 72(2):1052-9. PubMed ID: 9444999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
    Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
    Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.
    Berman PW
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S277-89. PubMed ID: 9814956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    Nara PL; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Gallo RC; Fischinger PJ; Goudsmit J
    J Virol; 1990 Aug; 64(8):3779-91. PubMed ID: 2370681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.
    Boyer JD; Cohen AD; Ugen KE; Edgeworth RL; Bennett M; Shah A; Schumann K; Nath B; Javadian A; Bagarazzi ML; Kim J; Weiner DB
    AIDS; 2000 Jul; 14(11):1515-22. PubMed ID: 10983638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
    J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella.
    Berggren RE; Wunderlich A; Ziegler E; Schleicher M; Duke RC; Looney D; Fang FC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):489-95. PubMed ID: 8548327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
    Berman PW; Gray AM; Wrin T; Vennari JC; Eastman DJ; Nakamura GR; Francis DP; Gorse G; Schwartz DH
    J Infect Dis; 1997 Aug; 176(2):384-97. PubMed ID: 9237703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
    Connor RI; Korber BT; Graham BS; Hahn BH; Ho DD; Walker BD; Neumann AU; Vermund SH; Mestecky J; Jackson S; Fenamore E; Cao Y; Gao F; Kalams S; Kunstman KJ; McDonald D; McWilliams N; Trkola A; Moore JP; Wolinsky SM
    J Virol; 1998 Feb; 72(2):1552-76. PubMed ID: 9445059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.
    Buonaguro L; Racioppi L; Tornesello ML; Arra C; Visciano ML; Biryahwaho B; Sempala SD; Giraldo G; Buonaguro FM
    Antiviral Res; 2002 Jun; 54(3):189-201. PubMed ID: 12062391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virus load in chimpanzees infected with human immunodeficiency virus type 1: effect of pre-exposure vaccination.
    ten Haaft P; Cornelissen M; Goudsmit J; Koornstra W; Dubbes R; Niphuis H; Peeters M; Thiriart C; Bruck C; Heeney JL
    J Gen Virol; 1995 Apr; 76 ( Pt 4)():1015-20. PubMed ID: 9049351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 40. Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees.
    Belo M; Yagello M; Girard M; Greenlee R; Deslandres A; Barré-Sinoussi F; Gluckman JC
    AIDS; 1991 Feb; 5(2):169-76. PubMed ID: 2031689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.